ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!
Issue link: https://eguideline.guidelinecentral.com/i/1518809
11 10 Table 9. Anemia: Recommendations (2017) COR LOE Recommendations IIb B-R In patients with NYHA class II and III HF and iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL if transferrin saturation is <20%), intravenous iron replacement might be reasonable to improve functional status and QoL. III: No Benefit B-R In patients with HF and anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality. Table 10. Treating Hypertension to Reduce the Incidence of HF: Recommendation (2017) COR LOE Recommendation I B-R In patients at increased risk, stage A HF, the optimal blood pressure in those with hypertension should be <130/80 mm Hg. Table 11. Recommendation for Hypertension in Stage C HFr EF (2017) COR LOE Recommendation I C-EO Patients with HFrEF and hypertension should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg. Table 12. Treating Hypertension in Stage C HFp EF: Recommendation (2017) COR LOE Recommendation I C-LD Patients with HFpEF and persistent hypertension aer management of volume overload should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg. Table 13. Sleep Disordered Breathing: Recommendations (2017) COR LOE Recommendations IIa C-LD In patients with NYHA class II–IV HF and suspicion of sleep disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable. IIb B-R In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness. III: Harm B-R In patients with NYHA class II–IV HFrEF and central sleep apnea, adaptive servo-ventilation causes harm. Treatment Table 8. Pharmacological Treatment for Stage C HFpEF: Recommendations (2017) COR LOE Recommendations I B Systolic and diastolic blood pressure should be controlled in patients with HFpEF in accordance with published clinical practice guidelines to prevent morbidity. I C Diuretics should be used for relief of symptoms due to volume overload in patients with HFpEF. IIa C Coronary revascularization is reasonable in patient with CAD in whom symptoms (angina) or demonstrable myocardial ischemia is judged to be having an adverse effect on symptomatic HFpEF despite GDMT. IIa C Management of AF according to published clinical practice guidelines in patients with HFpEF is reasonable to improve symptomatic HF. IIa C e use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. IIb B-R In appropriately selected patients with HFpEF (with EF ≥45%, elevated BNP levels or HF admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations. IIb B e use of ARBs might be considered to decrease hospitalizations for patients with HFpEF. III: No Benefit B-R Routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QoL in patients with HFpEF is ineffective. III: No Benefit C Routine use of nutritional supplements is not recommended for patients with HFpEF.